Metachronous mixed cellularity classical Hodgkin’s lymphoma and T-cell leukemia/lymphoma: A case report

Table 1 Proportion of CD3⁺CD4^-CD8 to 24 T-cell receptor variable β subfamilies in T-cells, with a significant increase in vβ14 (91.55%)

No	Name	Results	CD3+	Biological reference interval of CD3+CD4+	CD3+CD8+	Unit
1	Vβ5.3	0.19	0.37-2.98	0.36-2.10	0.32-2.64	%
2	Vβ7.1	0.34	0.64-20.01	0.59-3.80	0.87-7.14	%
3	Vβ3	0.59	0.52-15.71	0.66-10.04	0.32-13.80	%
4	Vβ9	0.38	1.10-9.30	0.78-8.24	1.16-7.67	%
5	Vβ17	0.36	2.28-12.61	3.12-8.32	1.83-11.18	%
6	Vβ16	0.15	0.42-1.90	0.34-1.80	0.02-2.24	%
7	Vβ18	0.03	0.58-5.23	0.72-3.35	0.02-2.76	%
8	Vβ5.1	0.45	3.19-14.93	4.67-10.94	1.12-8.92	%
9	Vβ20	0.07	0-9.73	0.04-5.30	0.08-5.61	%
10	Vβ13.1	0.36	1.62-8.16	1.93-7.70	0.41-5.35	%
11	Vβ13.6	0.30	0.84-8.80	0.86-3.40	0.47-4.56	%
12	Vβ8	0.46	2.26-29.47	2.94-6.73	0.86-11.43	%
13	Vβ5.2	0.15	0.49-4.98	0.50-2.87	0.18-3.53	%
14	Vβ2	1.25	4.03-23.48	5.43-12.84	1.65-12.42	%
15	Vβ12	0.24	1-4.76	1.08-2.80	0.33-3.33	%
16	Vβ23	0.02	0.28-4.76	0.13-1.90	0.04-5.13	%
17	Vβ1	0.49	1.89-11.70	1.62-14.20	1.40-8.21	%
18	Vβ21.3	0.23	1.08-5.97	1.53-4.7	0.54-4.93	%
19	Vβ11	0.05	0.25-5.11	0.30-1.90	0.14-2.25	%
20	Vβ22	0.23	1.99-9.89	1.98-8.48	0.54-6.47	%
21	Vβ14	91.55	1.33-8.03	1.57-4.68	1.50-14.3	%
22	Vβ13.2	0.39	0.80-5.28	0.72-7.27	0.96-9.62	%
23	Vβ4	0.04	0.79-3.26	1.20-2.83	0.61-4.34	%
24	Vβ7.2	0.06	0.05-5.45	0.00-3.10	0.01-12.10	%
25	The sum of the 24 subfamilies	98.38	69.95	72.25	66.58	%

Table 2 Previously reported and current cases of classical metachronous Hodgkin lymphoma and peripheral T-cell lymphoma

Age, y/sex	One (EBV)	Therapy for one	Other (EBV)	Therapy for other	Interal (mo)	BM infiltration	Outcome	Ref.
32/M	CHL (+)	ABVD	PTCL (-)	Unknown	24	Unknown	Unknown	Brown et al[11], 2004
77/F	PTCL (nd)	CHOP	CHL (nd)	Radiation therapy	48	Unknown	Unknown	Brown et al[11], 2004
34/F	CHL (?)	ABVD	PTCL (+)	CHOP, IVE, intermediate-dose MTX, ASCT, BV	47	No	Died after 26 mo	Meconi et al[12], 2020
54/M	CHL (nd)	MOPP, ABVD	PTCL (nd)	Unknown	24	No	Unknown	Wlodarsk et al[13], 1993
76/F	CHL (+)	ABVD	PTCL (+)	CHOP	108	No	Died after 5 mo	Oka et al[14], 2011
37/M	PTCL (nd)	IVAM, BEAM, ASCT	CHL (+)	ABVD	60	Yes	Died after 17 mo	Park et al[15], 2013
64/F	CHL (-)	ABVD	PTCL (-)	Etoposide, etc	15	Yes	Died after 9 mo	Chang and Lee[16], 2015
59/M	CHL (+)	ABVD, PDL-1	PTCL (-)	E-CHOP, DICE, chidamide	42	Yes	Died after 7 mo	Present study

EBV: Epstein-Barr virus; CHL: Classical metachronous hodgkin lymphoma; PTCL: Peripheral T-cell lymphoma. Nd: Not done; +: Positive; -: Negative; MOPP/ABVD: Mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine, dacarbazine; CHOP: Cyclophosphamide, doxorubicin, vincristine, prednisone; IVAM: Ifosfamide, etoposide, cytarabine, methotrexate; BEAM: Bendamustine, etoposide, cytarabine, melphalan; ASCT: Autologous peripheral blood stem cell transplant; IVE: Icyclophosphamide epirubicin etoposide; MTX: Methotrexate; BV: Brentuximab vedotin; E-CHOP: Etoposide CHOP; DICE: Icyclophosphamide, etoposide, cisplatin, dexamethasone; M: Male; F: Female.